Objective: This study aimed to determine the association between venous–arterial CO2 difference (Pv-aCO2) and clinical outcomes of interest in children with severe sepsis and septic shock. Design: An analytical observational study of a prospective cohort was conducted. Setting: The study was carried out from January 2015 to January 2018 in the pediatric intensive care unit of a referral hospital. Materials and methods: Of a total of 1159 patients who were admitted to pediatric critical care, 375 had severe sepsis and septic shock, of which 67 fulfilled the inclusion criteria. Arterial and venous gases were drawn simultaneously with a transthoracic echocardiogram, Pv-aCO2, and other measures of tissue perfusion such as arterial lactate, venous, and evolution to multiple organ failure. Measurements and main results: Half (53.7%) of the patients were under 24 months old, with a slight predominance of male patients. The main site of infection was the lungs in 56% of the cases, with a 91.2% survival rate. Patients who died had a higher venous lactate level (interquartile range 16.2–33.6, p = 0.02). However, there was no correlation between myocardial dysfunction seen on echocardiogram and a Pv-aCO2 greater than 6 mm Hg in children with severe sepsis and septic shock (r = 0.13). Pv-aCO2 and central venous saturation had low sensitivity to detect multiple organ failure and poor correlation with the number of compromised systems (r = 0.8). Conclusion: Pv-aCO2 was not associated with myocardial dysfunction, measured by echocardiogram, in children with severe sepsis and septic shock. It also did not correlate with the number of organs involved or mortality.
Introduction Hypertrophic Obstructive Cardiomyopathy (HOCM) is an important cause of sudden death and heart failure, specially in young adults. Approximately 5% to 8% of patients are not suitable for transcoronary ablation, if myectomy is not feasible, Endocardial Radiofrequency Ablation of Septal Hypertrophy (ERASH) has shown acceptable efficacy and safety for left ventricular outflow tract (LVOT) gradient reduction. 20 ERASH cases have been reported in the literature. Case report 39 year old woman with diagnosis of HOCM, symptoms of dyspnea (NYHA III), and aborted sudden death as first clinical manifestation; a cardiac defibrillator was implanted. A transthoracic echocardiogram (TTE) revealed normal left ventricle (LV) ejection fraction, moderate mitral regurgitation (systolic anterior valve motion), basal inter-ventricular septal wall thickness of 20 mm generating a LVOT gradient of 51 mmHg. A coronary angiography showed inadequate septal branch anatomy to perform alcohol ablation. The patient refused myectomy. Heart Team decided to perform ERASH. Using a 3D Cardiac Mapping System and 2D Echocardiography, the basal interventricular septum received 50 Watts/50˚C radiofrequency ablation without any acute complication. Three days later, a TTE showed LVOT gradient 26 mmHg. The description of the LV mechanics is described on Table 1. Pre and post ERASH ventricular mechanics was analyzed including circumferential endocardial and mesocardial strain and strain rate, as well as longitudinal strain involved in the LV segments that received ERASH (Figure 1.) . Conclusion We report the analysis of ventricular mechanics after a successful case of ERASH, an alternative technique for treating HOCM. In our analysis, pre- ERASH longitudinal strain was significantly more negative at the basal anterior and anteroseptal segments than the other LV segments. This may be a predictor of focal LV remodeling at these segments in the future. Table 1. Pre ERASH Post ERASH Ventricular Segment Strain Strain Rate Strain Strain Rate Longitudinal Strain Basal Anteroseptal -14.4% -1.2 1/s -7% -0.6 1/s Endocardial Circumferential Strain Basal Anteroseptal -13.7% -1.9 1/s -32% -2.2 1/s Basal Anterior -44.6% -4.2 1/s -18.6% -1.6 1/s Mesocardial Circumferential Strain Basal Anteroseptal -7.7% -1.0 1/s -20.2% -1.2 1/s Basal Anterior -24.9% -1.7 1/s -13.8% -0.9 1/s Left ventricular mechanics pre and post ERASH. Abstract P1708 Figure 1.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.